Personalized mRNA Vaccines Move Into the Melanoma Fight
Individually manufactured mRNA vaccines targeting tumor-specific neoantigens have entered clinical testing in melanoma, applying the pandemic-era platform to high-risk resected disease.
Topic
Topic
Individually manufactured mRNA vaccines targeting tumor-specific neoantigens have entered clinical testing in melanoma, applying the pandemic-era platform to high-risk resected disease.
Penn Medicine helped test a promising mRNA cancer vaccine, advancing a platform with direct implications for melanoma adjuvant th…